GILEAD SCIENCES, INC.
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- GILD [1]
- Listing exchanges
- Nasdaq [1]
- SEC industry
- Biological Products, (No Diagnostic Substances) [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- GILEAD SCIENCES, INC. [1]
- Headquarters location
- Foster City [2]
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404 [1]
- Founded
- 1987-06 [2]
- Legal form
- Delaware corporation [2]
- Incorporation jurisdiction
- Delaware, United States [1]
- Leadership in background record
- Daniel O'Day [2]
- Official website
- www.gilead.com ↗ [2]
- Employees
- 17,000 · reported year 2026 [2]
- Annual revenue
- USD 29,442,000,000 · reported year 2025 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US3755581036 [2]
- CIK
- 0000882095 [1]
- SIC code
- 2836 [1]
- Country in background record
- United States [2]
Company positioning and business
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. [3]
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. [3]
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. [3]
Background text: Wikipedia contributors, Gilead Sciences. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies Daniel O'Day in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Employees: 17,000 · reported year 2026. [2]
Annual revenue: USD 29,442,000,000 · reported year 2025. [2]
Financial year, securities and disclosures
The SEC submissions record gives GILEAD SCIENCES, INC. a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: GILD (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2836. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was GILEAD SCIENCES, INC. founded?
Founded: 1987-06. The linked source provides the background record. [2]
Where is the headquarters of GILEAD SCIENCES, INC.?
Headquarters location: Foster City. The linked source provides the background record. [2]
Which business sectors are recorded for GILEAD SCIENCES, INC.?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
GILEAD SCIENCES, INC. relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — GILEAD SCIENCES, INC. filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Gilead Sciences (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.